Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Bioventus (NASDAQ:BVS) is the #1 top healthcare stock out of 1073 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 41, which is 14 points higher than the healthcare sector average of 27. It passed 13 out of 33 due diligence checks and has strong fundamentals. Bioventus has seen its stock return 61.77% over the past year, overperforming other healthcare stocks by 82 percentage points.

Bioventus has an average 1 year price target of $15.00, an upside of 41.78% from Bioventus's current stock price of $10.58.

Bioventus stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Bioventus, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Jazz Pharmaceuticals (NASDAQ:JAZZ) is the #2 top healthcare stock out of 1073 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Jazz Pharmaceuticals (NASDAQ:JAZZ) is: Value: A, Growth: A, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: C.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a Due Diligence Score of 27, which is equal to the healthcare sector average of 27. It passed 9 out of 33 due diligence checks and has average fundamentals. Jazz Pharmaceuticals has seen its stock return 115.68% over the past year, overperforming other healthcare stocks by 136 percentage points.

Jazz Pharmaceuticals has an average 1 year price target of $237.67, an upside of 3.89% from Jazz Pharmaceuticals's current stock price of $228.77.

Jazz Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Jazz Pharmaceuticals, 58.33% have issued a Strong Buy rating, 33.33% have issued a Buy, 8.33% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Indivior Pharmaceuticals (NASDAQ:INDV) is the #3 top healthcare stock out of 1073 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Indivior Pharmaceuticals (NASDAQ:INDV) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Indivior Pharmaceuticals (NASDAQ:INDV) has a Due Diligence Score of 41, which is 14 points higher than the healthcare sector average of 27. It passed 14 out of 33 due diligence checks and has strong fundamentals. Indivior Pharmaceuticals has seen its stock return 232.07% over the past year, overperforming other healthcare stocks by 253 percentage points.

Indivior Pharmaceuticals has an average 1 year price target of $48.00, an upside of 30.58% from Indivior Pharmaceuticals's current stock price of $36.76.

Indivior Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Indivior Pharmaceuticals, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 74 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

So Young International (NASDAQ:SY) has an annual dividend yield of N/A, which is N/A percentage points lower than the healthcare sector average of 2.74%.

So Young International's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 29.37%, which is 27 percentage points higher than the healthcare sector average of 2.74%.

Dominari Holdings's dividend payout ratio of -19.1% indicates that its high dividend yield might not be sustainable for the long-term.

Embecta (NASDAQ:EMBC) has an annual dividend yield of 19.11%, which is 16 percentage points higher than the healthcare sector average of 2.74%.

Embecta's dividend payout ratio of 31.2% indicates that its high dividend yield is sustainable for the long-term.

Healthcare stocks were down -1.78% in the last day, and down -1.7% over the last week. Dare Bioscience was the among the top losers in the healthcare sector, dropping -24.13% yesterday.

Dare Bioscience shares are trading lower after the company reported worse-than-expected Q1 sales results.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 57, which is 42 points higher than the healthcare sector average of 15. It passed 4 out of 7 valuation due diligence checks.

Embecta's stock has dropped -73.07% in the past year. It has underperformed other stocks in the healthcare sector by -52 percentage points.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 86, which is 71 points higher than the healthcare sector average of 15. It passed 6 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 502.69% in the past year. It has overperformed other stocks in the healthcare sector by 523 percentage points.

Collegium Pharmaceutical (NASDAQ:COLL) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Collegium Pharmaceutical has a valuation score of 57, which is 42 points higher than the healthcare sector average of 15. It passed 4 out of 7 valuation due diligence checks.

Collegium Pharmaceutical's stock has gained 15.13% in the past year. It has overperformed other stocks in the healthcare sector by 36 percentage points.

60.48% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 42.57% over the next year.

4.98% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.31% of healthcare stocks are rated B (Buy), 47.89% are rated C (Hold), 28.23% are rated D (Sell), and 6.59% are rated F (Strong Sell).